NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Axitinib Therapy Management Study

WithdrawnN/A

Sponsor: Pfizer

Conditions: Renal Cell Carcinoma

Interventions: Inlyta, Bavencio, Keytruda

Countries: United States

The objectives of the study is to describe axitinib therapy management through use of the data to be generated by ConcertAI

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Confirmed diagnosis of aRCC (Stage III, Stage IV (M0) or Stage IV (M1)) at any point
* Age 18 years or older at the time of aRCC diagnosis
* Received a qualifying IO-containing combination (nivolumab and ipilimumab, axitinib and pembrolizumab, or axitinib and avelumab) in the first regimen after aRCC diagnosis or axitinib monotherapy in any line

Exclusion Criteria:

* none

Locations (1)

New York, New York, United States